Christine Walchuk is an associate in the firm’s Technology & Life Sciences Group. She joined Goodwin in 2015. 

Ms. Walchuk’s practice focuses on the representation of public and private life sciences companies in a broad range of commercial and intellectual property transactions. She advises clients regularly with respect to complex commercial transactions designed to maximize the value of pharmaceutical products and technology assets, including research and development collaborations, technology licenses and acquisitions, distribution and manufacturing agreements, and profit-sharing and co-promotion arrangements. Ms. Walchuk also counsels clients in connection with private financings, public offerings, spin-outs and M&A transactions with respect to intellectual property rights and operational risks.

In addition, Ms. Walchuk has specific experience counseling clients in strategic partnering and licensing transactions in various sectors of the agricultural biotechnology and plant sciences space, as well as clients in high-tech, software and Internet industries.

Areas of Practice
Domaines de Pratique





Some of Ms. Walchuk’s recent representative matters include:

  • Pieris Pharmaceuticals in its collaboration with Servier for the dual-checkpoint inhibitor PRS-332 and up to seven other immuno-oncology bispecific drug candidates, for a deal value of up to €1.7 billion
  • Teva Pharmaceuticals in its global agreement with Regeneron to develop and commercialize the phase 3 novel nerve growth factor antibody fasinumab and to share in its global commercial value, for $250 million upfront and the payment of ongoing R&D costs of approximately $1 billion
  • Intellia Therapeutics in its multi-year collaboration with Regeneron on CRISPR/Cas gene-editing technology for in vivo therapeutic development, with $75 million upfront and potential milestone and royalty payments
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb, valued up to $600 million with up-front and near-term payments of $225 million
  • Poseida Therapeutics, Inc. in its global agreement with Janssen to apply Centyrin technology in the development of chimeric antigen receptor (CAR) therapies*
  • Transposagen Biopharmaceuticals in its research collaboration and global license agreement with Janssen for allogeneic chimeric antigen receptor (CAR) T-cell therapies, with up to $292 million per CAR-T therapeutic in upfront and potential milestone payments in addition to potential royalty payments*

* Denotes experience prior to joining Goodwin.

Professional Experience

Prior to joining Goodwin, Ms. Walchuk was an associate in the Life Sciences practice group at Cooley LLP. She is a member of the Virginia State Bar and the American Bar Association.

In The News


Dans les Nouvelles




Lettres de Créance



J.D., Intellectual Property, 2008
University of Richmond Law School

(cum laude)

B.S., Human Biology, 2002
University of Montana

(highest honors)



District of Columbia
Get In Touch
Entrer en contact
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos clients comptent sur nous pour des services de conseil de classe mondiale, des conseils sur le travail transactionnel complexe et des litiges à enjeux élevés. Spécialisés dans les domaines de la finance, des sciences de la vie, du capital-investissement, de l'immobilier et de la technologie, nous utilisons une approche collaborative et interdisciplinaire pour résoudre les problèmes les plus complexes de nos clients. Pour en savoir plus, contactez-nous.


Search Other Lawyers
Recherche par Pratique